Candriam S.C.A. Incyte Corp Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Incyte Corp stock. As of the latest transaction made, Candriam S.C.A. holds 809,733 shares of INCY stock, worth $62.9 Million. This represents 0.31% of its overall portfolio holdings.

Number of Shares

809,733

Previous 1,319,681 38.64%

Holding current value

$62.9 Million

Previous $80 Million 33.1%

% of portfolio

0.31%

Previous 0.49%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $29.2 Million - $35 Million	-509,948 Reduced 38.64%	809,733 $53.5 Million
Q2 2024 Aug 05, 2024	SELL	$51.18 - $63.75 $7.89 Million - $9.82 Million	-154,116 Reduced 10.46%	1,319,681 $80 Million
Q1 2024 May 03, 2024	BUY	$56.55 - $66.59 $24.5 Million - $28.9 Million	433,508 Added 41.67%	1,473,797 $84 Million
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $2.4 Million - $2.95 Million	45,951 Added 4.62%	1,040,289 $65.3 Million
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $65,511 - $74,764	1,134 Added 0.11%	994,338 $57.4 Million
Q2 2023 Aug 08, 2023	BUY	$60.95 - $75.51 $9.51 Million - $11.8 Million	156,025 Added 18.64%	993,204 $61.8 Million
Q1 2023 May 12, 2023	SELL	$70.23 - $86.01 $2.15 Million - $2.64 Million	-30,650 Reduced 3.53%	837,179 $60.5 Million
Q4 2022 Feb 13, 2023	SELL	$67.18 - $84.11 $3.57 Million - $4.47 Million	-53,130 Reduced 5.77%	867,829 $69.7 Million
Q3 2022 Nov 10, 2022	BUY	$66.18 - $82.86 $12 Million - $15 Million	180,757 Added 24.42%	920,959 $61.4 Million
Q2 2022 Aug 03, 2022	SELL	$66.18 - $83.18 $764,842 - $961,311	-11,557 Reduced 1.54%	740,202 $56.2 Million
Q1 2022 May 13, 2022	SELL	$66.02 - $79.71 $1.5 Million - $1.81 Million	-22,683 Reduced 2.93%	751,759 $59.7 Million
Q4 2021 Feb 10, 2022	BUY	$63.34 - $74.11 $2.01 Million - $2.35 Million	31,702 Added 4.27%	774,442 $56.8 Million
Q3 2021 Nov 09, 2021	BUY	$68.67 - $84.02 $4.86 Million - $5.95 Million	70,846 Added 10.54%	742,740 $51.1 Million
Q2 2021 Jul 20, 2021	BUY	$79.87 - $87.53 $7.87 Million - $8.63 Million	98,596 Added 17.2%	671,894 $56.5 Million
Q1 2021 Apr 29, 2021	SELL	$76.02 - $100.5 $152 - $201	-2 Reduced -0.0%	573,298 $47.9 Million
Q4 2020 Jan 22, 2021	BUY	$80.74 - $97.7 $20.2 Million - $24.5 Million	250,608 Added 77.66%	573,300 $49.9 Million
Q3 2020 Oct 19, 2020	BUY	$85.07 - $109.69 $180,858 - $233,200	2,126 Added 0.66%	322,692 $29 Million
Q2 2020 Jul 23, 2020	BUY	$74.18 - $108.93 $2.27 Million - $3.33 Million	30,545 Added 10.53%	320,566 $33.3 Million
Q1 2020 May 26, 2020	BUY	$63.18 - $85.97 $1,137 - $1,547	18 Added 0.01%	290,021 $24.8 Million
Q4 2019 Jan 21, 2020	SELL	$73.04 - $95.72 $305,891 - $400,875	-4,188 Reduced 1.42%	290,003 $25,000
Q3 2019 Oct 21, 2019	SELL	$72.82 - $86.52 $7.3 Million - $8.68 Million	-100,305 Reduced 25.43%	294,191 $22,000
Q2 2019 Aug 01, 2019	SELL	$73.52 - $88.7 $7.31 Million - $8.82 Million	-99,439 Reduced 20.13%	394,496 $33.4 Million
Q1 2019 May 02, 2019	BUY	$63.56 - $88.17 $1.81 Million - $2.51 Million	28,413 Added 6.1%	493,935 $42.5 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $8.76 Million - $10.5 Million	149,727 Added 47.41%	465,522 $29.6 Million
Q3 2018 Nov 07, 2018	BUY	$61.75 - $74.23 $1.17 Million - $1.41 Million	18,935 Added 6.38%	315,795 $21.8 Million
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $125,776 - $173,586	2,067 Added 0.7%	296,860 $19.9 Million
Q1 2018 May 09, 2018	SELL	$83.06 - $100.98 $2.06 Million - $2.5 Million	-24,795 Reduced 7.76%	294,793 $24.6 Million
Q4 2017 Feb 07, 2018	SELL	$93.56 - $116.6 $7.03 Million - $8.76 Million	-75,170 Reduced 19.04%	319,588 $30.3 Million
Q3 2017 Nov 03, 2017	BUY	$109.15 - $138.27 $43.1 Million - $54.6 Million	394,758	394,758 $46.1 Million

Others Institutions Holding INCY

# of Institutions

640

Shares Held

187M

Call Options Held

729K

Put Options Held

479K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $17.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account